Retinal Drugs: Can Innovation Win Market Share?

Johnson & Johnson has agreed to pay US$2.2 billion upfront for Ollin Biosciences, betting that its investigational retinal treatment can challenge Roche’s Vabysmo. On the same day, 16 November 2026, Sandoz launched another Eylea biosimilar in the US, adding to the competitive pressure on established treatments.

Regeneron’s latest results show what’s at stake. US sales of its longer-lasting Eylea HD rose 62% in the third quarter, yet combined sales of Eylea and Eylea HD still fell 1% year on year. New treatments may help manufacturers defend their existing business, but translating product-level success into overall revenue growth is proving more difficult.

The developers seeking a foothold face a similar challenge. They must show whether improved disease control or fewer injections offer enough benefit to win market share as treatment options expand.

Visiongain Top Takeaways

  • J&J’s clinical wager: OLN324 has shown promising early results against Roche’s Vabysmo, but its Phase III trials use different comparators, leaving an important competitive question unresolved.
  • Regeneron’s revenue challenge: Eylea HD’s growth has not restored overall US franchise growth, while Sandoz has become the third company to launch an Eylea biosimilar in the US.
  • The limits of treatment durability: AbbVie and REGENXBIO are approaching pivotal gene therapy results, while EyePoint’s failed wet AMD trials demonstrate the importance of preserving vision alongside reducing injection frequency.

J&J’s Ollin Deal Worth Up to US$3.3bn Targets Roche’s Vabysmo

On 16 November 2026, Johnson & Johnson agreed to acquire Ollin Biosciences for US$2.2 billion upfront, with up to US$1.125 billion in milestone payments. The acquisition would add OLN324, an investigational treatment for wet age-related macular degeneration (AMD) and diabetic macular oedema (DME), to J&J’s ophthalmology portfolio.

Developed with Innovent Biologics, OLN324 targets VEGF and Ang2, the same pathways as Roche’s Vabysmo (faricimab). Its design aims to improve control of retinal swelling and potentially reduce how often patients need injections.

In the 164-patient Phase Ib JADE study, Ollin reported greater reductions in retinal swelling than Vabysmo in patients with DME. Improvements in vision were numerically greater, although the study primarily assessed safety and the efficacy findings remain exploratory. In wet AMD, overall reductions in retinal swelling were comparable.

Vabysmo generated CHF3.20 billion in global sales during the first nine months of 2026, up 10% at constant exchange rates, according to Roche’s latest results.

Under a separate agreement contingent on the acquisition closing, Blackstone Life Sciences will provide J&J with US$750 million over several years to fund OLN324’s Phase III development. Blackstone will be eligible to receive regulatory and sales milestone payments and single-digit royalties in return.

OLN324’s registered Phase III trials compare it with Eylea or Lucentis rather than Vabysmo. Those studies will therefore not directly establish whether the treatment offers an advantage over Roche’s established bispecific therapy.

Sandoz Enters a Crowded Eylea Biosimilar Market

On 16 November 2026, Sandoz launched Enzeevu (aflibercept-abzv) in the US, becoming the third company to introduce an Eylea 2 mg biosimilar after Amgen and Biocon. The FDA-approved treatment is interchangeable with Regeneron’s original Eylea across its approved indications.

Sandoz also announced a multi-year private-label agreement to supply Enzeevu through an additional US commercial channel from mid-2027, with committed purchase volumes. The commercial partner was not disclosed.

Regeneron’s third-quarter results show the pressure on its established product. US sales of Eylea fell 41% year on year to US$400 million, while Eylea HD, its higher-dose formulation designed for longer treatment intervals, grew 62% to US$699 million. Combined sales declined 1% to US$1.10 billion.

Regeneron attributed the original product’s decline to competition and patients moving to Eylea HD. Sandoz’s launch came after the quarter ended and did not contribute to those results.

Eylea HD’s growth has largely offset the decline in the original formulation, but has not yet returned the franchise to growth. Further biosimilar launches will increase the importance of the higher-dose product in defending Regeneron’s revenue.

AbbVie and REGENXBIO Face Pivotal AMD Gene Therapy Results

AbbVie and REGENXBIO expect Phase III results for surabgene lomparvovec (sura-vec, ABBV-RGX-314), an investigational one-time gene therapy for wet AMD, in the fourth quarter of 2026. The ATMOSPHERE and ASCENT trials, involving more than 1,300 patients, are testing whether the treatment can preserve vision as effectively as existing therapies, ranibizumab and aflibercept.

Sura-vec is designed to provide sustained anti-VEGF activity and reduce the need for repeated injections. Earlier-stage follow-up data showed stable or improved vision and fewer injections through five years in a small group of patients, although these findings require confirmation in the pivotal trials.

Unlike conventional retinal injections, sura-vec requires surgical administration beneath the retina. Even if it matches existing treatments in preserving vision, its commercial prospects will depend on whether fewer injections justify the procedure, its associated risks and treatment costs.

REGENXBIO expects regulatory submissions in 2027, subject to the trial results.

EyePoint Shifts to DME After Two Phase III Setbacks

EyePoint’s sustained-release retinal treatment DURAVYU (vorolanib intravitreal insert) failed to meet the primary endpoints in two Phase III wet AMD trials. LUGANO missed its target in August 2026, followed by LUCIA in October.

Both trials tested whether DURAVYU could preserve vision nearly as well as aflibercept while reducing injections. Treatment burden was 42% lower in LUGANO and 38% lower in LUCIA, but neither trial met its primary target for comparable visual outcomes. In LUCIA, patients gained an average of 2.5 letters on a standard vision chart, compared with 6.1 for aflibercept.

Following the October results, EyePoint announced plans to conclude the wet AMD trials early, reduce its workforce by approximately 53% and concentrate resources on diabetic macular oedema (DME). Its Phase II VERONA study had reported improved vision and fewer supplemental injections in DME patients.

EyePoint expects results from its two fully enrolled Phase III DME trials, COMO and CAPRI, in early Q4 2027. However, its 12 November financial update projects funding only into late Q3 2027, even after restructuring. The company may therefore need further financing or cost reductions before its next pivotal results.

Market Outlook: Growth Amid Pricing Pressure

Visiongain forecasts the global macular degeneration and other retinal diseases drugs market to grow from US$12.46 billion in 2026 to US$29.47 billion by 2036, at a CAGR of 9.0%.

Ageing populations and rising demand for retinal disease treatment will support growth, but revenue will not be distributed evenly. Biosimilar competition and the adoption of longer-acting therapies could shift sales between established and newer treatments, even as the overall market expands.

Visiongain Insight

A retinal drug can meet its clinical trial objectives without establishing why physicians should prescribe it over existing alternatives. OLN324’s Phase III trials compare it with Eylea or Lucentis rather than Vabysmo, leaving an important question about its competitive advantage over Roche’s treatment.

Longer-acting therapies face a different challenge. Fewer injections can benefit patients, but they do not necessarily mean fewer clinic visits, particularly where surgery or ongoing monitoring is required.

These distinctions matter when valuing retinal drug assets. Developers need evidence of clinical benefit, treatment burden and costs against the alternatives likely to be available at launch. A successful trial may support regulatory approval without establishing a commercial case for premium pricing , but winning market share will depend on demonstrating why clinicians should switch and healthcare systems should pay.

From Visiongain

Visiongain’s Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2026–2036 examines how biosimilar competition, longer-acting treatments and emerging therapies could influence market growth and competitive positioning. It includes detailed revenue forecasts by indication and treatment type, alongside analysis of the leading companies to support investment, portfolio and business development decisions.

The Ophthalmic Drugs Market Report 2026–2036 provides a wider perspective, covering retinal diseases, glaucoma, dry eye and other ophthalmic conditions. With forecasts across national markets and competitive analysis of more than 20 companies, it helps readers assess growth prospects and market opportunities across the ophthalmic pharmaceutical sector.

Explore the reports and request free sample pages to review the forecasts and analysis.

Press & Media Enquiries

Please contact press@visiongain.com for commentary, data requests or interview enquiries.

Clients & Partners

Deloitte logo
BAE systems logo
DUPONT logo
3M logo
BP logo
Daimler logo
Kelloggs logo
Honeywell logo
Lockhead Martin logo
Raytheon logo
Pfizer logo
TEVA logo
BAYER logo
THALES logo
Unilever logo
Shell logo
Mercedes logo
BASF logo